A modest investment of just over one hundred thousand dollars in seed funding is proving to be a powerful engine for cancer discovery, generating a sixfold return on investment and launching major clinical trials. New data from a leading cancer center shows that targeted pilot grants, typically ranging from $80,000 to $200,000, are helping researchers turn high risk ideas into funded studies that change how cancer is detected and treated.
These early stage grants fill a critical gap in cancer research. Federal agencies and major foundations usually require strong preliminary data before awarding large, multi-year grants. But generating that data requires money that researchers often do not have. Pilot funding provides that first step, allowing scientists to test a hypothesis and gather the evidence needed to compete for larger awards. At the Herbert Irving Comprehensive Cancer Center, investigators submit competitive proposals that are evaluated for scientific merit and potential impact. Selected projects are funded quickly, often within weeks, so teams can begin work without delay.
The results speak for themselves. More than six dollars in external funding is secured for every dollar invested in pilot grants. For example, when researcher Hee Won Yang received a Velocity Cancer Research Award in 2021 to study how breast cancer cells resist CDK4/6 inhibitors, his team used the seed money to uncover key biology. Within two years, that work led to major grants from the National Institutes of Health, the American Cancer Society, and the V Foundation. Similarly, Christine Chio used pilot funding to explore how pancreatic tumors evade immune detection. Her chemical proteomics approach laid the groundwork for an NIH R01 grant and awards from the Department of Defense and the Mark Foundation.
From Seed Funding to Patient Care
For physician-scientists, pilot grants can also accelerate the path to clinical trials. Ryan Moy, a doctor and researcher, received support through a Clinical Trialist Early Career Scholar program to study new treatments for diffuse gastric cancer. That early investment helped launch a Phase II clinical trial funded by Gateway for Cancer Research, bringing a promising therapy closer to patients. The cancer center tracks funded projects for years, measuring success not just by what happens during the award period but by what comes next, including new collaborations, publications, and additional trials.
The program is designed to support bold ideas that might not fit traditional funding models. As one program director noted, these awards give investigators the flexibility to pursue innovative questions and get that first leg up to launch larger projects. By investing in early stage science, the center is building a foundation for future breakthroughs and strengthening its ability to bring new therapies to patients. With the announcement of the 2026 awardees, researchers are already lining up to take that first step, turning small grants into discoveries that could change lives.